Actelion Pharmaceuticals US, Inc. secured FDA approval for the intravenous administration of UPTRAVI (selexipag) under NDA 214275 on July 29, 2021, a regulatory milestone expected to diversify the company's market offerings within the respiratory therapeutic space.